Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PESTO pilot study of obeticholic acid for portal hypertension in cirrhosis
2010-023241-29Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of obeticholic acid in Portal Hypertension (PH) and Cirrhosis (3 arms), sponsored by Intercept Pharmaceuticals. Primary endpoint: Improvement in portal pressure after 7 days. Started Dec 2010; status: completed.
02
Drugs
obeticholic acid
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on 2010-023241-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023241-29.